These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25669949)

  • 1. [The genetics of antipsychotic-related movement disorders].
    Bakker PR; van Os J; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):114-9. PubMed ID: 25669949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of tardive dyskinesia.
    Lee HJ; Kang SG
    Int Rev Neurobiol; 2011; 98():231-64. PubMed ID: 21907090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
    Cho CH; Lee HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk factors for tardive movement disorders in schizophrenia].
    Tenback DE; Bakker PR; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):120-4. PubMed ID: 25669950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study.
    Bakker PR; Bakker E; Amin N; van Duijn CM; van Os J; van Harten PN
    PLoS One; 2012; 7(5):e36561. PubMed ID: 22615781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genome-wide association analyses for neuroleptic-induced tardive dyskinesia].
    Arinami T; Inada T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):155-62. PubMed ID: 21941849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The catechol-O-methyl-transferase gene in tardive dyskinesia.
    Zai CC; Tiwari AK; Müller DJ; De Luca V; Shinkai T; Shaikh S; Ni X; Sibony D; Voineskos AN; Meltzer HY; Lieberman JA; Potkin SG; Remington G; Kennedy JL
    World J Biol Psychiatry; 2010 Sep; 11(6):803-12. PubMed ID: 20586531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
    Thelma B; Srivastava V; Tiwari AK
    Pharmacogenomics; 2008 Sep; 9(9):1285-306. PubMed ID: 18781856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacogenetics of antipsychotic treatment.
    Reynolds GP
    Handb Exp Pharmacol; 2012; (212):213-39. PubMed ID: 23129334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia: clinical presentation and treatment.
    van Harten PN; Tenback DE
    Int Rev Neurobiol; 2011; 98():187-210. PubMed ID: 21907088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia and deficit schizophrenia.
    Telfer S; Shivashankar S; Krishnadas R; McCreadie RG; Kirkpatrick B
    Acta Psychiatr Scand; 2011 Nov; 124(5):357-62. PubMed ID: 21838740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
    Lerer B; Segman RH; Fangerau H; Daly AK; Basile VS; Cavallaro R; Aschauer HN; McCreadie RG; Ohlraun S; Ferrier N; Masellis M; Verga M; Scharfetter J; Rietschel M; Lovlie R; Levy UH; Meltzer HY; Kennedy JL; Steen VM; Macciardi F
    Neuropsychopharmacology; 2002 Jul; 27(1):105-19. PubMed ID: 12062911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.
    Teng Y; Sandhu A; Liemburg EJ; Naderi E; Alizadeh BZ
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia and other movement disorders secondary to aripiprazole.
    Peña MS; Yaltho TC; Jankovic J
    Mov Disord; 2011 Jan; 26(1):147-52. PubMed ID: 20818603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of antipsychotics: Clinical utility and implementation.
    Arranz MJ; Salazar J; Hernández MH
    Behav Brain Res; 2021 Mar; 401():113058. PubMed ID: 33316324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe treatment-resistant tardive dystonia: is deep brain stimulation a treatment option].
    Mentzel CL; Tenback DE; Tijssen MA; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):125-31. PubMed ID: 25669951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Movement disorders due to modern antidepressants and mood stabilizers].
    Vandewalle W; Boon E; Sienaert P
    Tijdschr Psychiatr; 2015; 57(2):132-7. PubMed ID: 25669952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.